Skip to content

To study the efficacy of Niconrandil drug as an add-on treatment to the standard care given to the patient with acute ischemic stroke

Efficacy of Nicorandil as an add-on therapy to standard treatment in acute ischemic stroke- A Randomized, single blind, controlled clinical trial - ENCORE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039227
Enrollment
50
Registered
2022-01-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G94- Other disorders of brain in diseases classified elsewhere

Interventions

Intervention1: Nicorandil: Nicorandil 5mg tablet BD i.e twice a day for one month via oral route along with standard of care. Control Intervention1: standard of care: The standard therapy for stroke

Sponsors

SRMIST
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Age 18 -75 years. -Both genders. -Diagnosis of acute ischemic stroke. -More than 24 hours of onset of symptoms and not greater than 96 hours. -Modified Rankin scale greater than two. -Ability to ingest oral medication. -BMI >18.5 kg /m².

Exclusion criteria

Exclusion criteria: Haemorrhagic stroke. Hypotension with a SBP Patients on ACEIs and ARBs. Patients on steroids. Patients with respiratory compromise. Patients on antidepressant drugs. Severe acid peptic disease. Kidney dysfunction (GFR Intake of NSAID (exemption of Paracetamol). Severe unstable medical illnesses, including uncontrolled cardiac conditions or heart failure, cardiogenic shock (New York Heart Association Class III or IV). Use of any investigational agents within 30 days prior to screening. Pregnant women and lactating mothers. Severe hypovolemia. Severe liver dysfunction. Severe bradycardia ( Patients with G6PD deficiency. Clotting factor Deficiency

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale Timepoint: 0, 30 and 90 days

Secondary

MeasureTime frame
Barthel indexTimepoint: 0, 30 and 90 days

Countries

India

Contacts

Public ContactDr K Subramaniyan

SRM College of Pharmacy, SRMIST

ahalyap@srmist.edu.in8056125149

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026